Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$27 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-24.8 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
12.8
Industry P/E
--
EV/EBITDA
-1.2
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
29,550,970
CFO
$-18.68 Mln
EBITDA
$-38.95 Mln
Net Profit
$-29.03 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Neurosense Therapeutics (NRSN)
| 7.9 | -8.7 | 7.9 | -8.7 | -21.6 | -- | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
Company
|
2025
|
2023
|
|---|---|---|
|
Neurosense Therapeutics (NRSN)
| -35.9 | -35.7 |
|
BSE Sensex
| 9.1 | 18.7 |
|
BSE Sensex
| 9.1 | 18.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead... product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel. Address: Building B, Herzliya, Israel, 4672562 Read more
Chief Financial Officer
Mr. Or Eisenberg
Chief Financial Officer
Mr. Or Eisenberg
Headquarters
Herzliya
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Neurosense Therapeutics Ltd (NRSN) is $0.83 (NASDAQ) as of 02-Apr-2026 16:18 EDT. Neurosense Therapeutics Ltd (NRSN) has given a return of -21.56% in the last 3 years.
Since, TTM earnings of Neurosense Therapeutics Ltd (NRSN) is negative, P/E ratio is not available.
The P/B ratio of Neurosense Therapeutics Ltd (NRSN) is 12.82 times as on 31-Mar-2026, a 34 premium to its peers’ median range of 9.58 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
The 52-week high and low of Neurosense Therapeutics Ltd (NRSN) are Rs 2.60 and Rs 0.63 as of 03-Apr-2026.
Neurosense Therapeutics Ltd (NRSN) has a market capitalisation of $ 27 Mln as on 31-Mar-2026. As per SEBI classification, it is a company.
Before investing in Neurosense Therapeutics Ltd (NRSN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.07
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.